LIGAND PHARMACEUTICALS INCORPORATED Payments to Acquire Notes Receivable
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) reported Payments to Acquire Notes Receivable of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireNotesReceivable · last filed 2025-11-07
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for the quarter ending 2025-09-30 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for the quarter ending 2024-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for the quarter ending 2024-09-30 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for the quarter ending 2023-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for fiscal 2024 was $2.50M.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for fiscal 2023 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire notes receivable for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Notes Receivable 3 month | Payments to Acquire Notes Receivable 6 month | Payments to Acquire Notes Receivable 9 month | Payments to Acquire Notes Receivable 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $2.50M 10-K · filed 2025-02-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.50M 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $2.50M 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |